{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:44:26Z","timestamp":1792626266836,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11894-024-00924-w","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T05:02:01Z","timestamp":1707886921000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management"],"prefix":"10.1007","volume":"26","author":[{"given":"Matthew J.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","unstructured":"Giannetti MP, Weller E, Bormans C, Novak P, Hamilton MJ, Castells M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation\u2013related symptomatology including anaphylaxis. Annals Allergy, Asthma Immunol. 2021;126(6). https:\/\/doi.org\/10.1016\/j.anai.2021.01.016","DOI":"10.1016\/j.anai.2021.01.016"},{"key":"924_CR2","doi-asserted-by":"publisher","unstructured":"Hamilton MJ. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. Immunol Allergy Clin North Am. 2018;38(3). https:\/\/doi.org\/10.1016\/j.iac.2018.04.002","DOI":"10.1016\/j.iac.2018.04.002"},{"key":"924_CR3","doi-asserted-by":"publisher","unstructured":"Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6). https:\/\/doi.org\/10.1016\/j.jaci.2010.08.035","DOI":"10.1016\/j.jaci.2010.08.035"},{"key":"924_CR4","doi-asserted-by":"publisher","unstructured":"Kohn A, Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3). https:\/\/doi.org\/10.1007\/s12016-019-08755-8","DOI":"10.1007\/s12016-019-08755-8"},{"key":"924_CR5","doi-asserted-by":"publisher","unstructured":"Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One. 2011;6(10):e26375.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0026375","DOI":"10.1371\/journal.pone.0026375"},{"key":"924_CR6","doi-asserted-by":"publisher","unstructured":"Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2). https:\/\/doi.org\/10.1016\/j.jaci.2017.06.007","DOI":"10.1016\/j.jaci.2017.06.007"},{"key":"924_CR7","doi-asserted-by":"publisher","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11). https:\/\/doi.org\/10.1182\/blood-2016-09-731893","DOI":"10.1182\/blood-2016-09-731893"},{"key":"924_CR8","doi-asserted-by":"publisher","unstructured":"Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis. Blood. 2007;110(7). https:\/\/doi.org\/10.1182\/blood-2006-06-028100","DOI":"10.1182\/blood-2006-06-028100"},{"key":"924_CR9","doi-asserted-by":"publisher","unstructured":"Hamilton MJ, Frei SM, Stevens RL. The multifaceted mast cell in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(12). https:\/\/doi.org\/10.1097\/MIB.0000000000000142","DOI":"10.1097\/MIB.0000000000000142"},{"key":"924_CR10","doi-asserted-by":"publisher","unstructured":"Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12). https:\/\/doi.org\/10.1038\/ng.3696","DOI":"10.1038\/ng.3696"},{"key":"924_CR11","doi-asserted-by":"publisher","unstructured":"Giannetti MP, Akin C, Hufdhi R, et al. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. J Allergy Clin Immunology. 2021;147(4). https:\/\/doi.org\/10.1016\/j.jaci.2020.11.017","DOI":"10.1016\/j.jaci.2020.11.017"},{"key":"924_CR12","doi-asserted-by":"publisher","unstructured":"Hamilton MJ, Zhao M, Giannetti MP, et al. Distinct Small Intestine Mast Cell Histologic Changes in Patients with Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome. American Journal of Surgical Pathology. 2021;45(7). https:\/\/doi.org\/10.1097\/PAS.0000000000001676. Although there are no endoscopic or pathologic findings on intestinal biopsies specific to idiopathic mast cell activation syndrome, there are unique biopsy features in patients with Hereditary Alpha Tryptasemia. When this condition or systemic Mastocytosis are being considered, it is reasonable to stain for mast cells.","DOI":"10.1097\/PAS.0000000000001676"},{"key":"924_CR13","doi-asserted-by":"publisher","unstructured":"Novak P, Giannetti MP, Weller E, Hamilton MJ, Castells M. Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy. Annals of Allergy, Asthma and Immunology. 2022;128(3). https:\/\/doi.org\/10.1016\/j.anai.2021.10.006. This study provides objective evidence for the association between mast cell activation disorders and autonomic dysfunction and small fiber neuropathy in those who have neuropathic symptoms.","DOI":"10.1016\/j.anai.2021.10.006"},{"key":"924_CR14","doi-asserted-by":"publisher","unstructured":"Castells M, Austen KF. Mastocytosis: Mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127(2). https:\/\/doi.org\/10.1159\/000048188","DOI":"10.1159\/000048188"},{"key":"924_CR15","doi-asserted-by":"publisher","unstructured":"Degbo\u00e9 Y, Eischen M, Apoil P, et al. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. Osteoporosis International. 2019;30(6). https:\/\/doi.org\/10.1007\/s00198-019-04918-7","DOI":"10.1007\/s00198-019-04918-7"},{"key":"924_CR16","doi-asserted-by":"publisher","unstructured":"Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. American J Surg Pathol. 2014;38(6). https:\/\/doi.org\/10.1097\/PAS.0000000000000190","DOI":"10.1097\/PAS.0000000000000190"},{"key":"924_CR17","doi-asserted-by":"publisher","unstructured":"Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1). https:\/\/doi.org\/10.1016\/j.jaci.2011.04.037","DOI":"10.1016\/j.jaci.2011.04.037"},{"key":"924_CR18","doi-asserted-by":"publisher","unstructured":"Sokol H, Georgin-Lavialle S, Canioni D, et al. Gastrointestinal manifestations in mastocytosis: A study of 83 patients. J Allergy Clin Immunol. 2013;132(4). https:\/\/doi.org\/10.1016\/j.jaci.2013.05.026","DOI":"10.1016\/j.jaci.2013.05.026"},{"key":"924_CR19","doi-asserted-by":"publisher","unstructured":"Moura DS, Sultan S, Georgin-Lavialle S, et al. Evidence for cognitive impairment in mastocytosis: Prevalence, features and correlations to depression. PLoS One. 2012;7(6). https:\/\/doi.org\/10.1371\/journal.pone.0039468","DOI":"10.1371\/journal.pone.0039468"},{"key":"924_CR20","doi-asserted-by":"publisher","unstructured":"H\u00e4der T, Molderings GJ, Klawonn F, Conrad R, M\u00fccke M, Sellin J. Cluster-Analytic Identification of Clinically Meaningful Subtypes in MCAS: The Relevance of Heat and Cold. Dig Dis Sci. 2023;68(8). https:\/\/doi.org\/10.1007\/s10620-023-07921-5","DOI":"10.1007\/s10620-023-07921-5"},{"key":"924_CR21","doi-asserted-by":"publisher","unstructured":"Russell N, Jennings S, Jennings B, et al. The Mastocytosis Society Survey on Mast Cell Disorders: Part 2\u2014Patient Clinical Experiences and Beyond. J Allergy Clin Immunol: In Practice. 2019;7(4). https:\/\/doi.org\/10.1016\/j.jaip.2018.07.032","DOI":"10.1016\/j.jaip.2018.07.032"},{"key":"924_CR22","doi-asserted-by":"publisher","unstructured":"Wong S, Hasan S, Parducci C, Riley BA. The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome. AIMS Allergy Immunol. 2022;6(2). https:\/\/doi.org\/10.3934\/allergy.2022004","DOI":"10.3934\/allergy.2022004"},{"key":"924_CR23","doi-asserted-by":"publisher","unstructured":"Tu Y, Abell TL, Raj SR, Mar PL. Mechanisms and management of gastrointestinal symptoms in postural orthostatic tachycardia syndrome. Neurogastroenterol Motility. 2020;32(12). https:\/\/doi.org\/10.1111\/nmo.14031","DOI":"10.1111\/nmo.14031"},{"key":"924_CR24","doi-asserted-by":"publisher","unstructured":"Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural\u00a0Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome. J Allergy Clin Immunol. 2015;135(2). https:\/\/doi.org\/10.1016\/j.jaci.2014.12.1146","DOI":"10.1016\/j.jaci.2014.12.1146"},{"key":"924_CR25","doi-asserted-by":"publisher","unstructured":"Barber C, Kalicinsky C. A novel combination of an IgE mediated adult onset food allergy and a suspected mast cell activation syndrome presenting as anaphylaxis. Allergy, Asthma and Clin Immunol. 2016;12(1). https:\/\/doi.org\/10.1186\/s13223-016-0151-z","DOI":"10.1186\/s13223-016-0151-z"},{"key":"924_CR26","doi-asserted-by":"publisher","unstructured":"Wilder-Smith CH, Drewes AM, Materna A, Olesen SS. Symptoms of mast cell activation syndrome in functional gastrointestinal disorders. Scand J Gastroenterol. 2019;54(11). https:\/\/doi.org\/10.1080\/00365521.2019.1686059","DOI":"10.1080\/00365521.2019.1686059"},{"key":"924_CR27","doi-asserted-by":"publisher","unstructured":"Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65(1). https:\/\/doi.org\/10.1136\/gutjnl-2015-309151","DOI":"10.1136\/gutjnl-2015-309151"},{"key":"924_CR28","doi-asserted-by":"publisher","unstructured":"Weiler CR. Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis. J Allergy Clin Immunol: In Practice. 2020;8(2). https:\/\/doi.org\/10.1016\/j.jaip.2019.08.022","DOI":"10.1016\/j.jaip.2019.08.022"},{"key":"924_CR29","doi-asserted-by":"publisher","unstructured":"Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol. 2012;157(3). https:\/\/doi.org\/10.1159\/000328760","DOI":"10.1159\/000328760"},{"key":"924_CR30","doi-asserted-by":"publisher","unstructured":"Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4). https:\/\/doi.org\/10.1016\/j.jaci.2019.08.023","DOI":"10.1016\/j.jaci.2019.08.023"},{"key":"924_CR31","doi-asserted-by":"publisher","unstructured":"Valent P, Akin C, Nedoszytko B, et al. Diagnosis, classification and management of mast cell activation syndromes (Mcas) in the era of personalized medicine. Int J Mol Sci. 2020;21(23). https:\/\/doi.org\/10.3390\/ijms21239030","DOI":"10.3390\/ijms21239030"},{"key":"924_CR32","doi-asserted-by":"publisher","unstructured":"Lyons JJ. Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. Immunol Allergy Clin North Am. 2018;38(3). https:\/\/doi.org\/10.1016\/j.iac.2018.04.003","DOI":"10.1016\/j.iac.2018.04.003"},{"key":"924_CR33","doi-asserted-by":"publisher","unstructured":"Rama TA, Torrado I, Henriques AF, et al. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality. Journal of Allergy and Clinical Immunology: In Practice. 2023;11(3). https:\/\/doi.org\/10.1016\/j.jaip.2022.11.042","DOI":"10.1016\/j.jaip.2022.11.042"},{"key":"924_CR34","doi-asserted-by":"publisher","unstructured":"Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. Int Arch Allergy Immunol. 2019;180(1). https:\/\/doi.org\/10.1159\/000501079","DOI":"10.1159\/000501079"},{"key":"924_CR35","doi-asserted-by":"publisher","unstructured":"Butterfield JH. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome. J f Allergy Clin Immunol: In Practice. 2023;11(8). https:\/\/doi.org\/10.1016\/j.jaip.2023.02.017. Although the current gold standard laboratory test for mast cell activation is an elevation of tryptase 20%+2 ng\/mL over baseline, metabolites of mast cell mediators can also be tested in a 24-hour specimen during a period of symptoms and compared with baseline.","DOI":"10.1016\/j.jaip.2023.02.017"},{"key":"924_CR36","doi-asserted-by":"publisher","unstructured":"Shirley JF, Drourr J, Edwards WT, et al. Mast Cells in Patients with Hereditary \u03b1-Tryptasemia Promote HLA-DR Expression and a Th2-Polarizing Microenvironment in the Gastrointestinal Tract. The J Immunol. 2019;202(1_Supplement). https:\/\/doi.org\/10.4049\/jimmunol.202.supp.192.13","DOI":"10.4049\/jimmunol.202.supp.192.13"},{"key":"924_CR37","doi-asserted-by":"publisher","unstructured":"Panarelli NC, Hornick JL, Yantiss RK. What Is the Value of Counting Mast Cells in Gastrointestinal Mucosal Biopsies? Mod Pathol. 2023;36(2). https:\/\/doi.org\/10.1016\/j.modpat.2022.100005","DOI":"10.1016\/j.modpat.2022.100005"},{"key":"924_CR38","doi-asserted-by":"publisher","unstructured":"Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007;31(11). https:\/\/doi.org\/10.1097\/PAS.0b013e318078ce7a","DOI":"10.1097\/PAS.0b013e318078ce7a"},{"key":"924_CR39","doi-asserted-by":"publisher","unstructured":"Nguyen L, Wilson LA, Miriel L, et al. Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. Neurogastroenterology and Motility. 2020;32(8). https:\/\/doi.org\/10.1111\/nmo.13810","DOI":"10.1111\/nmo.13810"},{"key":"924_CR40","doi-asserted-by":"publisher","unstructured":"Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. J Allergy Clin Immunol: In Practice. 2019;7(4). https:\/\/doi.org\/10.1016\/j.jaip.2019.02.002","DOI":"10.1016\/j.jaip.2019.02.002"},{"key":"924_CR41","doi-asserted-by":"publisher","unstructured":"Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: A systematic review. Allergy: Europ J Allergy Clin Immunol. 2015;70(9). https:\/\/doi.org\/10.1111\/all.12672","DOI":"10.1111\/all.12672"},{"key":"924_CR42","unstructured":"Wasserman SI, Soter NA, Austen KF. The efficacy of oral disodium cromoglycate in human mastocytosis. J Allergy Clin Immunol. 1979;63(3)."},{"key":"924_CR43","doi-asserted-by":"publisher","unstructured":"Weng Z, Zhang B, Asadi S, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One. 2012;7(3). https:\/\/doi.org\/10.1371\/journal.pone.0033805","DOI":"10.1371\/journal.pone.0033805"},{"key":"924_CR44","doi-asserted-by":"publisher","unstructured":"Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production. Int Arch Allergy Immunol. 2008;147(4). https:\/\/doi.org\/10.1159\/000144042","DOI":"10.1159\/000144042"},{"key":"924_CR45","doi-asserted-by":"publisher","unstructured":"Berry R, Hollingsworth P, Lucas M. Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab. Clin Transl Immunol. 2019;8(10). https:\/\/doi.org\/10.1002\/cti2.1075","DOI":"10.1002\/cti2.1075"},{"key":"924_CR46","doi-asserted-by":"publisher","unstructured":"Lyons JJ, Metcalfe DD. Targeting Mast Cells with Biologics. Immunol Allergy Clin North Am. 2020;40(4). https:\/\/doi.org\/10.1016\/j.iac.2020.06.007","DOI":"10.1016\/j.iac.2020.06.007"},{"key":"924_CR47","doi-asserted-by":"publisher","unstructured":"Nicoloro SantaBarbara J, Lobel M. Depression, psychosocial correlates, and psychosocial resources in individuals with mast cell activation syndrome. J Health Psychol. 2022;27(9). https:\/\/doi.org\/10.1177\/13591053211014583","DOI":"10.1177\/13591053211014583"},{"key":"924_CR48","doi-asserted-by":"publisher","unstructured":"Nicoloro-SantaBarbara J, Carroll J, Lobel M. Coping, social support, and anxiety in people with mast cell disorders. Annals of Allergy, Asthma and Immunol. 2021;127(4). https:\/\/doi.org\/10.1016\/j.anai.2021.06.014. This paper is the first to provide objective data for the large burden of psychiatric disorders that often coexist in those with mast cell activation disorders.","DOI":"10.1016\/j.anai.2021.06.014"},{"key":"924_CR49","doi-asserted-by":"publisher","unstructured":"Govillard L, Gorbe\u00f1a S, Iraurgi I. Cognitive behavioral therapy with and without biofeedback in fibromyalgia: Assessment of functional and clinical change. Health Psychol Open. 2022;9(1). https:\/\/doi.org\/10.1177\/20551029221106044","DOI":"10.1177\/20551029221106044"},{"key":"924_CR50","doi-asserted-by":"publisher","unstructured":"Marshall GD, Tull MT. Stress, mindfulness, and the allergic patient. Expert Rev Clin Immunol. 2018;14(12). https:\/\/doi.org\/10.1080\/1744666X.2018.1536547","DOI":"10.1080\/1744666X.2018.1536547"},{"key":"924_CR51","doi-asserted-by":"publisher","unstructured":"Chey WD, Hashash JG, Manning L, Chang L. AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. Gastroenterology. 2022;162(6). https:\/\/doi.org\/10.1053\/j.gastro.2021.12.248","DOI":"10.1053\/j.gastro.2021.12.248"},{"key":"924_CR52","doi-asserted-by":"publisher","unstructured":"Jennings S, Russell N, Jennings B, et al. The mastocytosis society survey on mast cell disorders: Patient experiences and perceptions. J Allergy Clin Immunol: In Practice. 2014;2(1). https:\/\/doi.org\/10.1016\/j.jaip.2013.09.004","DOI":"10.1016\/j.jaip.2013.09.004"},{"key":"924_CR53","doi-asserted-by":"publisher","unstructured":"Haller E, Scarlata K. Diet Interventions for Irritable Bowel Syndrome: Separating the Wheat from the Chafe. Gastroenterol Clin North Am. 2021;50(3). https:\/\/doi.org\/10.1016\/j.gtc.2021.03.005","DOI":"10.1016\/j.gtc.2021.03.005"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-024-00924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-024-00924-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-024-00924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T22:35:57Z","timestamp":1711146957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-024-00924-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s11894-024-00924-w","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"29 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The author does not declare any conflict of interest","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain and novel studies with human or animal subjects performed by the author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}]}}